Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Novo Nordisk's new obesity drug trial data disappoints again Novo Nordisk on Monday revealed weaker-than-expected data from a second late ...

Mens Novo Nordisk tjener milliarder på fedmemedicin, bliver medicinalgigantens amerikanske medarbejderes pension investeret i junkfood Mens Novo Nordisk tjener styrtende på vægttabsmedicin ...

The table below is a review of notable updates that occurred in February 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage ...